New Research Demonstrates Clinical Effectiveness of Digital Treatment at Improving Insomnia and Comorbid Mental and Physical Health Issues
Retrieved on:
Monday, October 9, 2023
Page, Doctor of Philosophy, Anxiety, Cognitive behavioral therapy, Cerebrovascular disease, Sleep, Sleep medicine, Nation, Therapy, Psychology, Ageing, University, Dave's Picks Volume 38, Digital, Comorbidity, Disease, Cancer, Randomized controlled trial, Brain damage, Spectrum, Insomnia, Meta-analysis, DSM-IV codes, Journal of Affective Disorders, Research, Depression, SAN, Survivor, RCT, CBT, Nuffield Department of Population Health, ASCO, WSO, PMID, Disability, Systematic review, Canadian International Council, PMCID, Neurorehabilitation and Neural Repair, University of Oxford, Patient, Pharmaceutical industry, Nursing, Dietary supplement, Sleepio, Stroke
SAN FRANCISCO and OXFORD, England, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Big Health, the leader in digital therapeutics for the most common mental health conditions, announced today the publication of two, peer-reviewed studies demonstrating the effects of its flagship digital insomnia treatment Sleepio in individuals with co-morbid insomnia and clinically significant anxiety as well as in stroke survivors.
Key Points:
- Digital cognitive behavioral therapy (dCBT) has long been evidenced as an effective treatment for insomnia and anxiety — key findings from these studies provide new insights into Sleepio's impact.
- In a separate study among stroke survivors, 71% achieved remission using Sleepio compared to 30% of control participants.
- Individuals with insomnia are three times more likely to develop anxiety than healthy sleepers.
- [1] Additionally, comorbid insomnia and anxiety are associated with greater severity of both conditions — as well as increased symptoms of depression and poorer physical health.